Sign In
Buy TCRX
$0.97
-0.0080 (-0.82%)
At Close: Jun 03, 2026
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
04:25pm, Tuesday, 16'th Apr 2024
WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
04:01pm, Tuesday, 16'th Apr 2024
Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.
08:00am, Monday, 08'th Apr 2024
Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
07:00am, Tuesday, 02'nd Apr 2024
WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With
02:58pm, Sunday, 17'th Mar 2024
Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts.
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
09:16am, Wednesday, 06'th Mar 2024
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.78 per share a year ago.
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:00am, Wednesday, 06'th Mar 2024
Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are re
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
07:00am, Wednesday, 28'th Feb 2024
WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T c
All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101
